Evidence map›Paper›PMID 35332289›Full record

ArticleEye (London, England)2023

Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study.

Wenying Fan, Akihito Uji, Charles C Wykoff, David M Brown, Jano van Hemert, Khalil Ghasemi Falavarjani, Kang Wang, SriniVas R Sadda, Michael Ip

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01552408 (A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01552408 phase1 / phase2completednot on this map

A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE

TypeinterventionalSponsorDavid M. Brown, M.D.Ran2012 to 2017Enrolled29ConditionsDiabetic Macular EdemaArms0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Wenying FanBeijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Sciences Key Laboratory, Capital Medical University, Beijing, China.ORCID 0000-0003-1054-0599
Akihito UjiDoheny Image Reading Center, Doheny Eye Institute, Los Angeles, CA, USA.
Charles C WykoffRetina Consultants of Houston, Houston, TX, USA.
David M BrownRetina Consultants of Houston, Houston, TX, USA.
Jano van HemertOptos PLC, Dunfermline, UK.ORCID 0000-0003-0834-7079
Khalil Ghasemi FalavarjaniDoheny Image Reading Center, Doheny Eye Institute, Los Angeles, CA, USA.ORCID 0000-0001-5221-1844
Kang WangDoheny Image Reading Center, Doheny Eye Institute, Los Angeles, CA, USA.
SriniVas R SaddaDoheny Image Reading Center, Doheny Eye Institute, Los Angeles, CA, USA.
Michael IpDoheny Image Reading Center, Doheny Eye Institute, Los Angeles, CA, USA. ipmike333@gmail.com.
University of California, Los Angeles · USCornell University · USBeijing Tongren Hospital · CNDigital Catapult · GB

Funding

National Natural Science Foundation of China (National Science Foundation of China) Grant No. 81900863
6 · The paper itself

Abstract

purposeTo determine the relationship between baseline retinal non-perfusion area (NPA) and retinal vascular bed area (RVBA) on ultra-wide field fluorescein angiography (UWF FA) and long-term response to intravitreal ranibizumab therapy in diabetic macular oedema (DMO).

methodsA post-hoc, 2-year observational case series. Baseline UWF FA images (Optos 200Tx) of 40 eyes from 29 patients with diabetes mellitus and treatment naïve DMO in the DAVE (NCT01552408) study were montaged and stereographically projected at the Doheny Image Reading Center to adjust for peripheral distortion. The retinal vasculature was automatically extracted to calculate RVBA. NPA was manually delineated by two masked certified graders. RVBA and NPA were computed in mm

resultsWhile global NPA at baseline was not correlated to retinal thickness measurements, baseline NPA in the superior retina was associated with the macular volume (MV) improvement (P = 0.022). Multivariate analysis revealed a smaller RVBA at baseline was correlated with a better MV outcome at two-year follow-up after adjusting for confounding factors (P = 0.049).

conclusionEyes with smaller baseline RVBA appear to have a better long-term anatomic outcome of DMO.

Indexed as

Diabetes MellitusDiabetic RetinopathyMacular EdemaAngiogenesis InhibitorsFluorescein AngiographyHumansIntravitreal InjectionsRanibizumabRetinal VesselsTomography, Optical CoherenceAngiogenesis InhibitorsRanibizumab

Identifiers

PMID35332289
PMCPMC9998428
OpenAlexW4221071394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.